Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary named Engenra Biologics Private Limited on February 24, 2026. This strategic move is intended to expand the company’s contract manufacturing and other pharmaceutical production capabilities. The subsidiary was formed through an initial cash subscription of Rs. 10 lakhs for 100% equity, indicating an internal restructuring or expansion focus within its existing core business.
Formation of New Subsidiary Announced
Aurobindo Pharma Limited has officially disclosed the creation of a new wholly owned subsidiary on February 24, 2026. The entity has been named Engenra Biologics Private Limited, and it is registered in India. The incorporation represents a direct expansion initiative by the parent company.
Strategic Objectives and Structure
The primary objective for incorporating Engenra Biologics Private Limited is to facilitate the expansion of the group’s contract manufacturing and other pharmaceutical manufacturing operations. The subsidiary operates within the Pharmaceuticals industry sector.
Since Engenra Biologics Private Limited is newly incorporated, it currently has no historical turnover data available for the last three years.
Transaction Details
Aurobindo Pharma has acquired 100% of the shareholding in the new subsidiary. The transaction was executed via a 100% subscription to the share capital in cash. The initial cost of acquisition involves an initial subscription to the share capital totaling Rs. 10 lakhs, which is divided into 1,00,000 equity shares with a face value of Rs. 10/- each.
It is noted that this transaction constitutes a related party transaction, as the new entity is a wholly owned subsidiary. However, the report confirms that the promoters and promoter group of the Company are not interested in the transaction, implying it was conducted at arm’s length based on internal corporate strategy.
Source: BSE
